For patients battling neurodegenerative diseases like ALS, Parkinson’s, Alzheimer’s and other dementias, delivering disease-fighting antibody drugs directly to the brain has proven to be a difficult task. Our bodies set up tight walls to prevent infections from spreading to the brain, where they often become fatal.
Tumors possess myriad mechanisms to ensure their survival even at the peril of the host. Now scientists are delving deeper into how cancer cells alter the metabolism of specific amino acids to support the malignancy’s growth while simultaneously evading the antitumor activity of the host’s immune system.
ATLANTA, Oct. 20, 2026 /PRNewswire/ — UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the first self-administered once-daily autoinjector administration option for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive with ZILBRYSQ® (zilucoplan).¹ The autoinjector is designed to help simplify self-administration of ZILBRYSQ, offering patients another administration option and a more convenient treatment experience.2,3
A new blood test that could lead to earlier detection and treatment of breast cancer.
Exposure to hormone-disrupting chemicals may leave molecular changes that could someday help identify people at higher risk of breast cancer
A new computational approach reveals how cells communicate to assemble into tissues. This could accelerate stem cell engineering, improve disease models, and inform therapies.
The FDA clearance permits the motion-preserving device to be implanted across two levels in the cervical spine.
Research has revealed that the role of an important protein in colorectal cancer may vary significantly depending on which cells it is active in. The study, published in the journal npj Precision Oncology, shows that activity of a protein called mTOR may be associated with a stronger immune response in colorectal cancer when it is active in immune cells.
When replacing the aortic valve, a small aortic root can limit the size of the prosthetic valve that can be implanted. If the new valve is too small in relation to the patient’s body, the heart must continue to work against increased resistance—a so-called patient-prosthesis mismatch, which is associated with poorer clinical outcomes.
For several decades, researchers have sought to identify biomarkers capable of accurately predicting the outcome of an infection with a high-risk oncogenic HPV type. Despite significant advances, no viral, immune-related or molecular marker can currently and reliably predict which infections will regress spontaneously and which will progress to more severe disease.